CRISPR, Vertex dose first β-thalassemia patient, begin enrolling sickle cell patients in Phase I trials of CRISPR therapy

CRISPR Therapeutics AG (NASDAQ:CRSP) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) dosed the first patient in a Canadian and European Phase I/II trial of CTX001 to treat transfusion-dependent β-thalassemia,

Read the full 272 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE